ImmuPharma plc (LON:IMM – Get Free Report)’s stock price fell 6.2% during trading on Wednesday . The company traded as low as GBX 2.82 ($0.03) and last traded at GBX 2.89 ($0.04). 2,005,850 shares traded hands during trading, a decline of 90% from the average session volume of 19,540,998 shares. The stock had previously closed at GBX 3.08 ($0.04).
ImmuPharma Stock Down 7.8 %
The business’s fifty day moving average is GBX 1.65 and its 200 day moving average is GBX 1.70. The firm has a market capitalization of £11.83 million, a price-to-earnings ratio of -284.00 and a beta of 1.53.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Read More
- Five stocks we like better than ImmuPharma
- What Are Earnings Reports?
- SAP’s Strong Momentum: A Bullish Setup for Investors
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- BlackRock Breaks Records: Why the Stock Still Has Room to Run
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Duke vs. NRG: Which Energy Stock Will Power Higher Gains?
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
